Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $45.00.
Several research firms recently commented on SLN. The Goldman Sachs Group began coverage on shares of Silence Therapeutics in a research report on Tuesday, February 11th. They issued a "sell" rating and a $6.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, January 29th. BMO Capital Markets reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Finally, William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th.
View Our Latest Stock Analysis on Silence Therapeutics
Shares of NASDAQ SLN opened at $4.77 on Thursday. The stock has a market cap of $142.77 million, a P/E ratio of -3.04 and a beta of 1.05. Silence Therapeutics has a twelve month low of $4.06 and a twelve month high of $27.72. The stock has a 50 day moving average of $5.71 and a two-hundred day moving average of $11.94.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SLN. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after acquiring an additional 5,233 shares during the period. Barclays PLC boosted its position in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after purchasing an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics during the 4th quarter worth $69,000. Finally, Virtus ETF Advisers LLC grew its stake in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after purchasing an additional 6,098 shares during the period. Institutional investors and hedge funds own 98.73% of the company's stock.
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.